Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674755 | 1.00 | HSD17B1 (0.57) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL30229852 | 0.84 | HSD17B1 (0.57) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL1684295 | 0.84 | HSD17B1 (0.57) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL6632095 | 0.84 | HSD17B1 (0.57) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL2088201 | 0.84 | HSD17B1 (0.57) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL30937218 | 0.82 | HSD17B1 (0.55) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28786422 | 0.82 | HSD17B1 (0.55) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL10945242 | 0.82 | HSD17B1 (0.55) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL19512929 | 0.82 | HSD17B1 (0.55) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL29460303 | 0.82 | HSD17B1 (0.55) | HSD17B1HSD17B2SIGMAR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858943-B1 | SURFACE TREATMENT AGENT | DAIKIN IND LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-11814537-B2 | Silane compound containing perfluoro (poly ) ether group | DAIKIN INDUSTRIES, LTD. (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814537-B2 | Silane compound containing perfluoro (poly ) ether group | DAIKIN INDUSTRIES, LTD. (JP) | 2023-11-14 | — | — | US | disclosed |
| WO-2023210400-A1 | HEAT-CURABLE PERFLUOROPOLYETHER RUBBER COMPOSITION | 信越化学工業株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-11760062-B2 | Article having surface treatment layer | DAIKIN INDUSTRIES, LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11760062-B2 | Article having surface treatment layer | DAIKIN INDUSTRIES, LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20230273348-A1 | SURFACE TREATMENT COMPOSITION | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230273348-A1 | SURFACE TREATMENT COMPOSITION | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230257528-A1 | SURFACE TREATING COMPOSITION | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257528-A1 | SURFACE TREATING COMPOSITION | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-08-17 | — | — | US | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| US-20080114120-A1 | Coating composition | SHIN-ETSU CHEMICAL CO. LTD. | 2008-05-15 | — | — | US | disclosed |
| US-20080114120-A1 | Coating composition | SHIN-ETSU CHEMICAL CO. LTD. | 2008-05-15 | — | — | US | disclosed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN3A, SCN2A | HSD17B1 3952/4885HSD17B2 3809/4885SIGMAR1 1088/4885 |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | HSD17B1 928/4885HSD17B2 1146/4885SIGMAR1 1258/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HSD17B1 389/4885HSD17B2 279/4885SIGMAR1 63/4885 |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | HSD17B1 1086/4885HSD17B2 993/4885SIGMAR1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.